UNSPSC 51144503: Prolintane hydrochloride

This classification denotes a central nervous system stimulant C15H23N.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier YEG124534B, chemically known as pyrrolidine, 1-(1-(phenylmethyl)butyl)-, hydrochloride, but more generally known as prolintane hydrochloride, which bears US NIH Compound Identifier 14591. European Medicines Agency schedules Prolintane hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB04064MIG.

Most nations, for tariff and trade purposes, schedule prolintane hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, PROLINTANE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. SMILES: CCCC(CC1CCCCC1)N2CCCC2.CL.

UNSPSC 51144503 Prolintane hydrochloride is a Commodity code that nominally covers a specific central nervous system stimulant pharmaceutical. However, recent state and local procurement activity shows little direct demand for prolintane itself; instead, jurisdictions are soliciting broader pharmaceutical supply and opioid-response products under related codes and cooperative purchasing frameworks. The actual buying pattern under this code tier reflects state and local governments' procurement of prescription pharmaceuticals, over-the-counter products, and emergency medical supplies through wholesale distribution networks and direct-to-manufacturer relationships. Issuing bodies include state health and human services departments, county health systems, and multistate cooperative purchasing alliances that aggregate demand across participating state and local agencies.

Geographic activity centers on Texas and Minnesota. The Texas Health and Human Services Commission issued an RFI (HHS0017013, due Apr 3, 2026) to explore direct-to-manufacturer prescription contracting models outside traditional pharmacy benefit managers and wholesalers, signaling state-level interest in alternative pharmaceutical supply chains. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released an RFP (S1070000015802, due Mar 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products across participating state and local government facilities in Minnesota and Oregon, with awarded vendors to be provided to authorized wholesalers by May 15, 2026 and contracts effective July 1, 2026. Separately, Seminole County, Florida issued an IFB (IFB60459723LAS, due Jul 26, 2023) for naloxone and drug deactivation systems (1,900 units of naloxone and 800 deactivation systems annually) to support community health initiatives with quarterly deliveries, though this opportunity addresses opioid response rather than prolintane-specific demand. No recent solicitations specifically name prolintane hydrochloride as a line-item pharmaceutical requirement.